ibandronate sodium

FDA Drug Profile — ibandronate sodium, Ibandronate Sodium

Drug Details

Generic Name
ibandronate sodium
Brand Names
ibandronate sodium, Ibandronate Sodium
Application Number
ANDA202671
Sponsor
Mylan Institutional LLC
NDC Codes
2
Dosage Forms
INJECTION, SOLUTION, INJECTION
Routes
INTRAVENOUS
Active Ingredients
IBANDRONATE SODIUM

Indications and Usage

1 INDICATIONS AND USAGE Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women. (1.1) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (1.2) 1.1 Treatment of Postmenopausal Osteoporosis Ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, ibandronate sodium injection increases bone mineral density (BMD) and reduces the incidence of vertebral fractures [ see Clinical Studies (14) ] . 1.2 Important Limitations of Use The safety and effectiveness of ibandronate sodium injection for the treatment of osteoporosis are based on clinical data of one year duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.